Effect of Botulinum Toxin on Selective Motor Control and Pain in Diplegic Cerebral Palsy

Launched by GAZIOSMANPASA RESEARCH AND EDUCATION HOSPITAL · Sep 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called Botulinum Neurotoxin-A (BoNT-A) on children with diplegic cerebral palsy, which is a condition that affects movement and muscle control. The goal is to see if injecting BoNT-A into tight muscles can help reduce pain and improve the ability to control movement. The study is currently looking for participants between the ages of 4 and 12 who have been diagnosed with cerebral palsy and meet certain criteria, such as not having received this treatment in the last six months.

If your child is eligible and decides to participate, they will receive the BoNT-A injection and will be monitored for any changes in pain and motor control. It's important to note that children with certain conditions, such as severe mobility issues or those who have had specific surgeries, may not be able to join the trial. Overall, this study aims to find new ways to help children with diplegic cerebral palsy manage their symptoms and improve their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with Cerebral Palsy
• • Between the ages of 4-12
• • GMFCS (Gross Motor Function Classification System)1-4
• • Patients who have received an appropriate indication for BoNT-A injection from an experienced physiatrist
• • Patients who have not had botulinum toxin administered in the last 6 months
• Exclusion Criteria:
• • Mental retardation
• • GMFCS 5
• • Have an intrathecal baclofen pump for spasticity treatment or history of soft tissue and/or bone surgery
• • Underwent dorsal rhizotomy
• • Have an active infection or a localized skin infection at the injection site
• • Using aminoglycoside antibiotics
• • Contracture